摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dimethyl 3-aminoglutaconate | 63547-62-6

中文名称
——
中文别名
——
英文名称
dimethyl 3-aminoglutaconate
英文别名
dimethyl 3-aminopent-2-enedioate;dimethyl-3-enamino-glutarate;Dimethyl-β-aminoglutaconat
dimethyl 3-aminoglutaconate化学式
CAS
63547-62-6
化学式
C7H11NO4
mdl
——
分子量
173.169
InChiKey
CIDSYVVJNVVERM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    75-80 °C
  • 沸点:
    130-132 °C(Press: 2.8 Torr)
  • 密度:
    1.168±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0
  • 重原子数:
    12
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    78.6
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2922499990

SDS

SDS:a5209dc47a45d9d30cf31afa9603eedd
查看

反应信息

  • 作为反应物:
    描述:
    dimethyl 3-aminoglutaconate盐酸 、 sodium tetrahydroborate 、 硫酸1,1-dimethylethylaminoborane三乙胺 作用下, 以 四氢呋喃甲醇乙醇二氯甲烷异丙醇 为溶剂, 反应 28.0h, 生成 3-氨基-1,5-戊二醇
    参考文献:
    名称:
    [EN] PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    [FR] PYRIMIDINES ET VARIANTES DE CELLES-CI, ET LEURS UTILISATIONS
    摘要:
    本公开提供嘧啶化合物及其用途,例如用于治疗与P2X嘌呤受体相关的疾病。在某些方面,本公开提供P2X3和/或P2X2/3拮抗剂,这些拮抗剂可用于治疗内脏器官、心血管和与疼痛相关的疾病、症状和障碍。
    公开号:
    WO2017160569A1
  • 作为产物:
    描述:
    1,3-丙酮二羧酸二甲酯碳酸氢铵 作用下, 以 甲醇 为溶剂, 反应 40.0h, 生成 dimethyl 3-aminoglutaconate
    参考文献:
    名称:
    [EN] PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    [FR] PYRIMIDINES ET VARIANTES DE CELLES-CI, ET LEURS UTILISATIONS
    摘要:
    本公开提供嘧啶化合物及其用途,例如用于治疗与P2X嘌呤受体相关的疾病。在某些方面,本公开提供P2X3和/或P2X2/3拮抗剂,这些拮抗剂可用于治疗内脏器官、心血管和与疼痛相关的疾病、症状和障碍。
    公开号:
    WO2017160569A1
点击查看最新优质反应信息

文献信息

  • NOVEL PROCESS FOR THE PREPARATION OF 3-AMINO-PENTAN-1,5-DIOL
    申请人:Cleary Thomas
    公开号:US20080312467A1
    公开(公告)日:2008-12-18
    The present invention provides a novel method for preparing a key intermediate, 3-amino-pentan-1,5-diol (2), which is useful for the preparation of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)-propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidine-7-one (1) a MAP-kinase inhibitor useful in the treatment of rheumatoid arthritis.
    本发明提供了一种新的制备关键中间体3-氨基戊-1,5-二醇(2)的方法,该中间体可用于制备6-(2,4-二氟苯氧基)-2- [3-羟基-1-(2-羟乙基)-丙基氨基] -8-甲基-8H-吡啶[2,3-d]嘧啶-7-酮(1),该MAP-激酶抑制剂可用于治疗类风湿性关节炎。
  • Substituted 1,4-dihydropyridine compounds as bradykinin antagonists
    申请人:Pfizer Inc.
    公开号:US20030176445A1
    公开(公告)日:2003-09-18
    This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y is —(CH 2 ) m —, —C(O)— or —S(O)—; R 1 and R 2 are independently C 1-4 alkyl; R 3 is C 7-9 bicycloalkyl, C 5-7 azacycloalkyl or C 7-9 azabicycloalkyl, the C 7-9 bicycloalkyl, C 5-7 azacycloalkyl or C 7-9 azabicycloalkyl being optionally substituted with one, two or three substituents are independently selected from oxo, hydroxyl, C 1-4 alkyl, C 1-4 alkyloxy, C 1-4 alkyl-carbonyl, formyl, C 1-4 alkylenedioxy, and phenyl-C 1-4 alkyl; R 4 is thiazolyl, imidazolyl or oxazolyl, the thiazolyl, imidazolyl or oxazolyl being optionally substituted with one or two substituents independently selected from C 1-4 alkyl and halo; R 5 is hydrogen or C 1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.
    本发明提供了式(I)的化合物或其药学上可接受的盐,其中A是独立的卤素;Y是-(CH2)m-,-C(O)-或-S(O)-;R1和R2独立地是C1-4烷基;R3是C7-9双环烷基,C5-7杂环烷基或C7-9杂双环烷基,其中C7-9双环烷基,C5-7杂环烷基或C7-9杂双环烷基可以选用一个、两个或三个取代基,所述取代基独立地选自氧代、羟基、C1-4烷基、C1-4烷氧基、C1-4烷基羰基、甲酰基、C1-4亚烷基二氧基和苯基-C1-4烷基;R4是噻唑基、咪唑基或噁唑基,所述噻唑基、咪唑基或噁唑基可以选用一个或两个取代基,所述取代基独立地选自C1-4烷基和卤素;R5是氢或C1-4烷基;m为0、1或2;n为0、1、2、3、4或5。这些化合物可用于治疗由缓激肽介导的医疗状况,如炎症、过敏性鼻炎、疼痛等。本发明还提供了包含上述化合物的制药组合物。
  • 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists
    申请人:——
    公开号:US20010046993A1
    公开(公告)日:2001-11-29
    This invention provides a compound of the formula (I): 1 or the pharmaceutically acceptable salts thereof wherein A is independently halo; Y 1 is —(CH 2 ) m —, C(O) or S(O); Y 2 is N or CH; R 1 and R 2 are independently C 1-4 alkyl; R 3 is selected from the following: (a) optionally substituted —(CH 2 ) p —C 3-7 cycloalkyl; (b) optionally substituted —C 5-7 alkyl; and (c) substituted —C 1-4 alkyl; and (d) optionally substituted C 7- bicycloalkyl; R 4 is optionally substituted thiazolyl, imidazolyl or oxazolyl; X is S, —NH, —N—C 1-4 alkyl or O; R 5 is hydrogen or C 1-4 alkyl; R 6 is C 1-4 alkyl or halo; m is 0, 1 or 2; n is 0, 1, 2, 3, 4 or S; and p is 0, 1, 2, 3, 4, 5 or 6. These compounds are useful for the treatment of medical conditions caused by bradykinin such as inflammation, cardiovascular disease, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.
    该发明提供了化合物(I)的结构式或其药学上可接受的盐,其中:A独立地表示卤素;Y1表示-(CH2)m-、C(O)或S(O);Y2表示N或CH;R1和R2独立地表示C1-4烷基;R3选自以下物质:(a) 可选取代的-(CH2)p-C3-7环烷基;(b) 可选取代的-C5-7烷基;(c) 取代的-C1-4烷基;以及(d) 可选取代的C7-双环烷基;R4是可选取代的噻唑基、咪唑基或噁唑基;X表示S、-NH、-N-C1-4烷基或O;R5表示氢或C1-4烷基;R6表示C1-4烷基或卤素;m为0、1或2;n为0、1、2、3、4或S;p为0、1、2、3、4、5或6。这些化合物可用于治疗由激肽酶引起的医疗状况,如炎症、心血管疾病、疼痛等。该发明还提供了包含上述化合物的制药组合物。
  • Process for preparing 1,4-dihydropyridine compounds
    申请人:Pfizer Inc.
    公开号:US20030078430A1
    公开(公告)日:2003-04-24
    A process for preparing a 1,4-dihydropyridine compound comprising contacting an enamine compound 1 and a compound having a structure of 2 in the presence of a base; and treating the reaction mixture thus obtained in the presence of an acid or a combination of acids under mild reaction conditions. A resulting 1,4-dihydropyridine compound is useful as an anti-inflammatory agent or the like.
    一种制备1,4-二氢吡啶化合物的方法,包括在碱存在下接触恩酰胺化合物1和具有结构2的化合物,并在温和反应条件下在酸或酸的组合物存在下处理所得到的反应混合物。所得到的1,4-二氢吡啶化合物可用作抗炎药物等。
  • 1,4-dihydropyridine compounds as bradykinin antagonists
    申请人:——
    公开号:US20020161006A1
    公开(公告)日:2002-10-31
    The present invention relates to compounds of the formula 1 wherein each A is independently halo; Y is —(CH 2 ) m —, —C(O)— or —S(O)—; R 1 and R 2 are independently C 1-4 alkyl; R 3 is substituted azacycloalkyl etc.; R 4 is phenyl substituted at the 2-position with a substituent selected from substituted C 1-7 alkyl, substituted C 1-7 alkoxy, amine, etc; R 5 is hydrogen or C 1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.
    本发明涉及公式1的化合物,其中每个A独立地是卤素;Y是—(CH2)m—,—C(O)—或—S(O)—;R1和R2独立地是C1-4烷基;R3是取代的氮杂环烷基等;R4是苯基,在2位被取代,取代基为取代的C1-7烷基,取代的C1-7烷氧基,胺等;R5是氢或C1-4烷基;m为0、1或2;n为0、1、2、3、4或5。本发明还涉及包含这些化合物的制药组合物以及在治疗和预防炎症、哮喘、过敏性鼻炎、疼痛和其他疾病中使用这些化合物的用途。
查看更多